SynthesisPloS one2017
An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies.
Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Trial
- Article
- Atherogenic Lipoprotein Burden, Metabolic Stress and Immune Activation Associated with Coronary Atherosclerosis in Patients with Psoriasis.International journal of molecular sciences · 2026Article
- Divergent immunometabolic reprogramming in psoriasis and atopic dermatitis: a tale of two inflammatory skin diseases.Frontiers in immunology · 2026Review
- Stem Cell Therapy: A New Approach and Effective Treatment for Psoriasis.Dermatology practical & conceptual · 2025Review
- Metabolic syndrome and dermatological diseases: association and treatment.Nutrition & metabolism · 2025Review
- Skin Metabolic Signatures of Psoriasis and Psoriasis Concurrent with Metabolic Syndrome.Journal of inflammation research · 2025Article
- Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Factors Associated with Anxiety, Depression, and Quality of Life in Patients with Psoriasis: A Cross-Sectional Study.Brain sciences · 2024Article
- Clinical Implications of Metabolic Syndrome in Psoriasis Management.Diagnostics (Basel, Switzerland) · 2024Article
- Metabolic dysfunction associated steatotic liver disease in patients with plaque psoriasis: a case-control study and serological comparison.Frontiers in medicine · 2024Article
- Metabolic Syndrome Screening and Nutritional Status of Patients with Psoriasis: A Scoping Review.Nutrients · 2023Article
- Investigating the epidemiological relationship between vitiligo and psoriasis: a population-based study.Archives of dermatological research · 2023Article
- Paradoxical Reactions to Anti-TNFα and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?Dermatology and therapy · 2023Review
- Psoriasis and associated risk factors: a cross-sectional analysis of the Brazilian Longitudinal Study of Adult Health.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Higher IL-9 Level is Associated with Psoriasis Vulgaris Complicated by Metabolic Syndrome.Clinical, cosmetic and investigational dermatology · 2023Article
- Trajectories of systemic agent use and associated depression- and anxiety-related health care costs among patients with psoriasis.JAAD international · 2022Article
- Carotid intima-media thickness in patients with psoriasis with and without metabolic syndrome.Archivos de cardiologia de Mexico · 2022Article
- Oversight and Management of Women with Psoriasis in Childbearing Age.Medicina (Kaunas, Lithuania) · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The relationship between psoriasis and metabolic syndrome is not well understood. Though multiple epidemiologic studies have suggested a link between psoriasis and metabolic syndrome, there is a lack of a comprehensive meta-analysis synthesizing the results of all available observational studies to date. In this meta-analysis, we examined global data on the relationship between psoriasis and odds of metabolic syndrome by searching for studies published between 1946-2016. Specifically, we analyzed the results from 35 observational studies from 20 countries with 1,450,188 total participants, of which 46,714 were psoriasis patients. The pooled odds ratio based on random effects analysis was 2.14 (95% CI 1.84-2.48). Publication bias was present, as evidenced by an Egger test and graphical visualization through a funnel plot (p = 0.001). Based on this comprehensive meta-analysis, psoriasis patients have higher odds of having metabolic syndrome when compared with the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.